Phase 2
๐ Investigational Drug / Biologic
NCT06651593
Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
๐ Md Anderson Cancer Center โ Houston, Texas
View Study & Screener โ